Express Pharma

Divis Labs Choutuppal Unit-1 gets US FDA nod

18

The inspection was concluded with 483 observations

Divis Laboratories Choutuppal Unit 1 in Telangana was recently undergone an US FDA inspection. This was a routine cGMP inspection by the US health regulator. The inspection has been concluded with 483 observations.

Divis Laboratories is in the process of building two additional production blocks at this facility; hence, from a growth perspective, this is an important unit.

Divis Laboratories is a research-focused contract manufacturing player (bulk drugs/intermediates). The company undertakes custom manufacturing of APIs and production of advanced intermediates, thus offering a competitive advantage to its clients over the entire life cycle of the products.

 

Comments are closed.